Ampicillin Stability in a Portable Elastomeric Infusion Pump: A Step Forward in Outpatient Parenteral Antimicrobial Therapy

Pharmaceutics. 2023 Aug 8;15(8):2099. doi: 10.3390/pharmaceutics15082099.

Abstract

Outpatient parenteral antimicrobial therapy (OPAT) with continuous infusion pumps is postulated as a very promising solution to treat complicated infections, such as endocarditis or osteomyelitis, that require patients to stay in hospital during extended periods of time, thus reducing their quality of life and increasing the risk of complications. However, stability studies of drugs in elastomeric devices are scarce, which limits their use in OPAT. Therefore, we evaluated the stability of ampicillin in sodium chloride 0.9% at two different concentrations, 50 and 15 mg/mL, in an elastomeric infusion pump when stored in the refrigerator and subsequently in real-life conditions at two different temperatures, 25 and 32 °C, with and without the use of a cooling device. The 15 mg/mL ampicillin is stable for up to 72 h under refrigeration, allowing subsequent dosing at 25 °C for 24 h with and without a cooling device, but at 32 °C its concentration drops below 90% after 8 h. In contrast, 50 mg/mL ampicillin only remains stable for the first 24 h under refrigeration, and subsequent administration at room temperature is not possible, even with the use of a cooling system. Our data support that 15 mg/mL AMP is suitable for use in OPAT if the volume and rate of infusion are tailored to the dosage needs of antimicrobial treatments.

Keywords: ampicillin; elastomeric pump; outpatient parenteral antimicrobial therapy; stability.

Grants and funding

This work was partially supported by Axencia Galega Innovación (Grupos de Potencial Crecimiento IN607B2020/11). A.C.-B., E.B.-V., I.V.-R., F.J.T.-C., C.M.-G. and A.F.F. acknowledge the support of the Instituto de Salud Carlos III (ISCIII) (research grants CM21/00114, CM20/00135, CM22/00055, CM22/00146, JR20/00026 and JR18/00014). J.M. acknowledges the support of Xunta de Galicia (GAIN) through the Senior Talent Research grant (11_IN858A_2021_1141142).